Juan Diego Freire Florez

Juan Diego Freire Florez

Auto-generated profile, based on publicly available information

Juan Diego Freire Florez

Departmental University Psychiatry Hospital of Valle, Cali, Colombia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2026 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
VOVivien Obitulata
Vivien Obitulata
KSKush Sehgal
Kush Sehgal
JFJuan Diego Freire Florez
Juan Diego Freire Florez
MMMichelle Mussi
Michelle Mussi
NNNeil Nero
Neil Nero
AAAkhil Anand
Akhil Anand
Purpose: Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. Procedures: We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Findings: Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=−0.79; 95% CI=−0.95 to −0.63; P <0.001) and drinking days (MD=−7.93; 95% CI=−11.03 to −4.83; P <0.001). No significant effect was observed for heavy drinking days (MD=−0.95; 95% CI=−2.12 to 0.22; P =0.11), with high heterogeneity ( I ²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P =0.007); other adverse events did not differ from placebo. Implications: Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide’s GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.